Category : Healthcare and Pharmaceuticals | Published at : November-2020 | Delivery Format : PDF | Status: Published | Pages : 190
The market for clinical microbiology is expected to grow at a CAGR of around 6.9% from 2020 to 2027 and expected to reach the market value of around US$ 6.5 Bn by 2027.
Clinical Microbiology is a branch of medical science that deals with the prevention, diagnosis, and treatment of infectious diseases. It is associated with the various clinical applications of microbes for the improvement of health. Additionally, the four kinds of microorganisms that cause infectious diseases include bacteria, fungi, parasites, and viruses.
Market Dynamics
The technological advancements in disease diagnostics and rising incidence of infectious diseases and growing outbreaks of epidemics are supporting the market growth. The increased funding and public-private investments are also major factors bolstering market growth. The market is facing challenges due to the COVID-19 pandemic in the manufacturing and supply chain process as the delivery of the product to the end-user is disrupted. Furthermore, improving healthcare infrastructure across emerging countries are anticipated to provide potential opportunities over the forecast timeframe from 2020 to 2027.
On the other side, limited reimbursement policies for microbiology testing procedures are likely to restrict the growth to an extent throughout the forecast timeframe from 2020 to 2027.
Segment Instance
Pharmaceutical is leading the market with maximum revenue share
In 2019, the pharmaceutical segment by application having potential revenue share (%) owing to the presence of well-established and globally accepted regulations that govern the evaluation of microbial contamination during pharmaceutical manufacturing and raw material sourcing. The presence of various regulatory bodies like WHO, FDA, Medicines and Healthcare Products Regulatory Agency (MHRA, UK), European Medicines Evaluation Agency (EU), Therapeutic Goods Administration (TGA), Australia, and the Brazilian Health Regulatory Agency is supporting the growth of the pharmaceutical segment.
Hospitals and Diagnostic Centers by end user accounted for the maximum revenue share (%) in 2019
The high incidences of diseases like tuberculosis, HIV-AIDS, malaria, and epidemic diseases and the necessity to treat these diseases in the hospitals and diagnostic centers are supporting the segmental market growth. The availability of advance products and trained professionals to operate the instruments for the treatment of infectious diseases are supporting the regional market growth.
North America is leading the market with maximum revenue share
North America along with its major economies including the US and Canada is leading the clinical microbiology market. The advanced healthcare infrastructure and the presence of major players in the region are supporting the highest market value. The high penetration of clinical microbiology technologies among key end-users in the region and well-established distribution channels for clinical microbiology product manufacturers and suppliers is accelerating the regional market value. The ongoing investment in the healthcare sector by the major players for the development of advancements in the healthcare sector is further propelling the supporting the regional market growth. Moreover, the region is also projected to maintain its dominance throughout the forecast period from 2020 to 2027.
Key Market Players
The players profiled in the report include Abbott Laboratories (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Merck KGaA (US), bioMerieux S.A., Cepheid Inc., Danaher Corporation, Bruker Corporation, Becton Dickinson & Company, Hologic Inc., Roche Diagnostics, and Alere Inc. The major market players were involved in mergers and acquisitions, partnerships & collaborations, and new product development for the expansion of market share.
Market Segmentation
Market By Product
Instruments
- Laboratory Instruments
- Microbiology Analyzers
Reagents
- Pathogen-Specific Kits
- General Reagents
Market By Disease
Respiratory Diseases
Bloodstream Infections
Gastrointestinal Diseases
Sexually Transmitted Diseases
Urinary Tract Infections
Periodontal Diseases
Other Indications
Market By Application
Pharmaceutical Applications
Energy Applications
Chemical & Material Manufacturing Applications
Clinical Applications
Food Testing Applications
Environmental Applications
Market By End User
Hospitals and Diagnostic Centers
Academic and Academic and Research Institutes
Custom Lab Service Providers
Market By Geography
North America
- U.S.
- Canada
Europe
- UK.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for clinical microbiology is expected to reach a market value of around US$ 6.5 Bn by 2027.
The clinical microbiology market is expected to grow at a CAGR of around 6.9% from 2020 to 2027.
The hospitals and diagnostic centers is the leading segment by end user in the clinical microbiology market.
The technological advancements in disease diagnostics and rising incidence of infectious diseases, and increased funding and public-private investments are some of the factors driving the market growth.
Abbott Laboratories (US), Thermo Fisher Scientific (US), Agilent Technologies (US), Merck KGaA (US), bioMerieux S.A., Cepheid Inc., Danaher Corporation, Bruker Corporation, Becton Dickinson & Company, Hologic Inc., Roche Diagnostics, and Alere Inc. are the prominent players in the market.
North America held the highest market share in the clinical microbiology market
The report provides insights on global clinical microbiology market segment by product, disease, application, end users and major geographic regions.
